BioMérieux obtained 510 (k) clearance last year for its Vitek Reveal ID/AST system as part of its current five-year growth plan.

Labor Dr. Wisplinghoff will offer GTC's next-generation sequencing-based tests for solid tumor and hematologic neoplasms.

Quest said it aims through the collaboration to streamline data management, improve data analytics, and personalize the experiences of its patients.

The investment bank said Bio-Techne is a premium growth asset with a strong core business and growth verticals.

The firm said that a strong start to the commercialization of its Liaison Plex platform also aided growth in its molecular diagnostics business.

Last week, readers were most interested in a story about how blood-based testing is making increasing inroads for neurological conditions.

According to the government, these providers submitted false claims to MassHealth for urine drug tests and home health services.

The instrument is used for advanced immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization applications.

The firm's Italian distributor A.D.A. is beginning a four-hospital study in collaboration with the Italian Society for Clinical Microbiology to evaluate the system.

The firm is preparing for a trial to show the efficacy of its CyPath Lung test and support a submission to the US Food and Drug Administration for marketing clearance.